Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
about
Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.Ibrutinib in the real world patient: many lights and some shades.Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival.Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.
P2860
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy and safety of front-l ...... li CLL Study Group experience.
@ast
Efficacy and safety of front-l ...... li CLL Study Group experience.
@en
type
label
Efficacy and safety of front-l ...... li CLL Study Group experience.
@ast
Efficacy and safety of front-l ...... li CLL Study Group experience.
@en
prefLabel
Efficacy and safety of front-l ...... li CLL Study Group experience.
@ast
Efficacy and safety of front-l ...... li CLL Study Group experience.
@en
P2093
P2860
P1433
P1476
Efficacy and safety of front-l ...... li CLL Study Group experience.
@en
P2093
Aaron Polliack
Andrea Braester
Aviv Ariel
Erel Joffe
Israeli CLL Study Group
Lev Shvidel
Mika Shapiro
Naomi Rahimi-Levene
Neta Goldschmidt
Osnat Bairey
P2860
P304
P356
10.3324/HAEMATOL.2014.115808
P577
2015-02-06T00:00:00Z